What the FDA labels say about taking them together
Midazolam and oxymorphone
Midazolam's FDA label (Nayzilam) of January 19, 2023 names oxymorphone in its drug interactions section; oxymorphone's label does not name midazolam itself but warns about its class (Benzodiazepines). The midazolam label: “The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. …”
Check it at the source: the midazolam FDA label on DailyMed (effective January 1, 2024, Fresenius Kabi USA, LLC); the oxymorphone FDA label on DailyMed (effective June 29, 2026, Aurolife Pharma, LLC).
What does the midazolam label say about oxymorphone?
Nayzilam label (UCB, Inc., January 19, 2023), drug interactions7.2 Opioids Clinical Impact: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. … Intervention: Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required [see ]. Examples: Morphine, hydrocodone, oxymorphone, codeine, fentanyl
Source: FDA drug label (Nayzilam, NDA211321), UCB, Inc., effective January 19, 2023 (SPL set 2b29422e-54d5-4a49-8522-e9cf752368c3), via openFDA
Source: FDA drug label (Midazolam), Fresenius Kabi USA, LLC, effective January 1, 2024 (SPL set 1cc9ba6e-fa1b-405e-9de8-720c567b2a73), via openFDA; the full label on DailyMed
What does the oxymorphone label say about midazolam?
Oxymorphone's label does not name midazolam itself; it warns about its class (Benzodiazepines):
Oxymorphone label, boxed warningRisks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
Oxymorphone label, boxed warningConcomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
Source: FDA drug label (Oxymorphone Hydrochloride), Aurolife Pharma, LLC, effective June 29, 2026 (SPL set 22c7652a-aa16-4fa8-89d9-517e69059068), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Midazolam | Oxymorphone | |
|---|---|---|
| Labeled for | n/a | Pain |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.233 per mL 2 mg/2 mL vial | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once